Business Wire

Regulatory Framework for E-cigarettes Essential in Moroccan and Algerian Markets as Prevalence of Smoking Expected to Rise Notably By 2025

17.5.2022 16:26:00 EEST | Business Wire | Press release

Share

RELX International, a responsible multinational electronic cigarettes company, is urging decision-makers in Morocco and Algeria to roll out comprehensive regulatory frameworks for e-cigarettes, ahead of an expected surge in smoking habits. Longstanding research has shown that smoking traditional, tobacco-based cigarettes poses significant health risks.

According to data compiled by website GSTHR.org (Global State of Tobacco Harm Reduction), there has been an upward trend in current smoking prevalence in the general population in Morocco.

In 2015, overall prevalence was estimated to be 23%, with a projection to increase to 28% by 2025 in Morocco. [1]. While in Algeria, current smoking trends for the overall adult population is also projected to increase, with an estimate of 16.9% by 2025 as per GSTHR.org. [2].

In contrast to traditional cigarettes, e-cigarettes are increasingly being hailed as a better alternative and can even help adult smokers reduce or quit smoking entirely according to several organisations, including the UK’s National Health Service (NHS). The service has found that e-cigarettes are around 95% less harmful than tobacco and have the potential to help smokers quit entirely [3]. A first of its kind clinical trial conducted by the Queen Mary University of London also found e-cigarettes are almost twice as effective as nicotine replacement treatments, such as patches and gum, at helping smokers to quit [4].

As more governments and health authorities endorse the benefits of e-cigarettes based on scientific testing – and given the expected increase in smoking habits in Morocco and Algeria, authorities should roll out risk-proportionate regulatory frameworks to govern the import, marketing and distribution of e-cigarettes. By doing so, adult smokers in both countries will have access to quality products from brands such as RELX that comply with international and local quality and safety health regulations, are priced accessibly, and are imported and distributed legally, in support of the economy.

Should these markets remain unregulated, it is likely that illicit trade will grow significantly, and see the markets seeded with counterfeit products of questionable quality. These products could pose a significant risk to smokers’ health and could end up in the hands of those under the legal age.

Links:

[1] Smoking, vaping, HTP, NRT and snus in Morocco

[2] Smoking, vaping, HTP, NRT and snus in Algeria

[3] E-cigarettes around 95% less harmful than tobacco estimates landmark review

[4] E-cigarettes more effective than nicotine replacement therapies, finds major UK clinical trial

[5] CBP, FDA Seize Counterfeit, Unauthorized E-Cigarettes

Notes to Editors

RELX International

Founded in 2019, RELX International is a multinational electronic cigarettes company that markets and sells RELX, The World’s Advanced vape brand powered by SuperSmooth™ technology. RELX, Asia’s leading e-cigarette brand, is widening its footprint across the world, and it is currently available in 40+ countries such as the UK, France, Italy, Germany, Indonesia, Philippines, Canada, KSA and the UAE. What sets RELX apart from competition is the fact that it has a full ecosystem (such as closed pods, disposables, device, and power bank accessories) that are designed at a cutting-edge research and development center and produced at one of the world’s largest e-cigarette factories. RELX's mission is to make RELX a trusted brand for legal age adult smokers through state-of-the-art products, industry-leading technologies, and scientific advances in collaboration with talented and committed people around the globe. The company has attracted global talents from Uber, Procter & Gamble, Apple, Beats, and L'Oréal. RELX is proud to be listed in Dubai Duty Free, the first duty free channel in the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further media information, samples and or images, please contact Khyati Megchiani or Mutasem Shadid at Brazen MENA:
relxarabia@brazenmena.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye